Manufacturer record
Pure & Cure Healthcare Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
28 batches manufactured by Pure & Cure Healthcare Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between September 2019 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
28 records linked to Pure & Cure Healthcare Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Pantoprazole Tablets IP | AGW01AKAMfg 2025-09 · Exp 2027-08 | The sample does not conform to IP standards. It fails the test Dissolution.Dissolution | DTL, KonniState lab | Jul 2026 |
| Levocetirizine & Montelukast Sodium Dispersible tablets | ABC04ABAMfg 2025-12 · Exp 2027-11 | The sample does not conform to Label claim with respect to content of Montelukast in Montelukast sodium)Labelling | Drugs Testing Laboratory, Madurai-19State lab | Jul 2026 |
| Phenazone & Lidocaine Hydrochloride Ear Drops -5ml | AOT01ACBMfg 2026-01 · Exp 2027-12 | ContentOther | DTL, Chennai-25State lab | Jun 2026 |
| Flunarizine Tablets IP 10mg | AUJ01AQAMfg 2025-08 · Exp 2028-07 | Sample fails the Descriptive part for tablets as per IP.Other | DTL ThiruvananthapuramState lab | Feb 2026 |
| Flunarizine Tablets IP 10mg | AUJ01AQAMfg 2025-08 · Exp 2028-07 | sample fails the test 'Descriptive Part' for tablets as per IP, as specified in the laboratory protocol.Other | DTL ThiruvananthapuramState lab | Jan 2026 |
| Albendazole Tablets IP 400 mg (ALBISTI ? 400) | PI28AH05Mfg 2023-07 · Exp 2025-12 | The Sample does not conform to standard in respect of the test for DissolutionDissolution | State Drugs Testing Laboratory, Agartala, TripuraState lab | May 2025 |
| Progaba Gel (Lidocaine Hydrochloride & Gabapentin Gel) | PSWAB66Mfg 2024-06 · Exp 2025-11 | Sample does not conform to Label claim with respect to the content of GabapentinLabelling | DTL MaduraiState lab | Apr 2025 |
| Ondansentron Tablets IP 4mg | PS39AB06Mfg 2023-06 · Exp 2025-05 | The sample does not comply with IP requirements for Dissolution testDissolution | CDTL MumbaiCDSCO lab | Apr 2025 |
| Lidocaine Hydrochloride and Gabapentin Gel (Gabaneuron Gel) | PWBBO7Mfg 2024-06 · Exp 2025-11 | Sample does not conform to lebel claim with respect to the content of GabapentinOther | DTL MaduraiState lab | Apr 2025 |
| Octenidine Dihydrochlordie Gel | PPKAC84Mfg 2023-05 · Exp 2026-04 | Sample does not conform to label claim with respect to the content of Octenidine Dihydrochloride.Labelling | DTL MaduraiState lab | Dec 2024 |
| Montair LC Kid (Montelukast Sodium & Levocetirizne Hydrochloride Dispersible Tablets) | AFB23W73Mfg 2023-09 · Exp 2025-08 | Uniformity of Dispersion & Assay of Montelukast SodiumAssay | CDL KolkataCDSCO lab | Aug 2024 |
| Calcium And Vitamin D3 Tablets IP Shelcal 500 (Shelcal) | GDXD0581Mfg 2023-08 · Exp 2025-07 | Description, Identification of Vitamin D3, Dissolution of Calcium and Assay of Calcium & Vitamin D3Assay | CDL KolkataCDSCO lab | Aug 2024 |
| Domperidone and Naproxen Sodium Tablets (Naxdom 500) | FHA0966Mfg 2023-12 · Exp 2026-11 | Not applicableOther | Not applicableState lab | Apr 2024 |
| Trypsin, Bromelain & Rutoside Trihydrate Tablets | PF8CC12Mfg 2023-08 · Exp 2025-07 | Assay of 'Trypsin'Assay | CDL KolkataCDSCO lab | Jan 2024 |
| Telmisartan and Chlorthalidone Tablets | PF8C006Mfg 2022-09 · Exp 2024-08 | Dissolution of ChlorthalidoneDissolution | CDL KolkataCDSCO lab | Aug 2023 |
| SHELCAL�-500 (Calcium And Vitamin D3 Tablets I.P.) | 8LV2H077Mfg 2021-06 · Exp 2023-05 | Identification of Vitamin D3, Dissolution (Calcium) and Assay of Elemental Calcium & Vitamin D3Assay | RDTL GuwahatiState lab | Nov 2022 |
| Alprasafe - 0.5 (Alprazolam Tablets I.P. 0.5 mg) | PE25AD01Mfg 2021-10 · Exp 2024-03 | Dissolution & Uniformity of ContentDissolution | CDL KolkataCDSCO lab | Nov 2022 |
| L - Methylfolate Tablets | PF8CY03Mfg 2022-04 · Exp 2024-03 | DescriptionDescription | CDL KolkataCDSCO lab | Oct 2022 |
| DIVALPROEX SODIUM TABLETS IP 500 mg | PF8AO19Mfg 2021-07 · Exp 2023-06 | Dissolution (Buffer stage)Dissolution | CDTL HyderabadCDSCO lab | Sep 2022 |
| Clopidogrel and Aspirin Tablets I.P. | PR14AD14Mfg 2022-02 · Exp 2024-01 | Free Salicylic Acid (Related Substances for Aspirin)Related substances | CDL KolkataCDSCO lab | Sep 2022 |
| Acebrophylline Capsules 100 mg | PF8AA04Mfg 2020-11 · Exp 2022-10 | Water ContentWater content | CDL KolkataCDSCO lab | May 2022 |
| Calcium with Vitamin D3 Tablets IP (SHELCAL-500 TABLETS) | GAVB0034Mfg 2021-01 · Exp 2022-12 | Assay of Vitamin D3 and uniformity of weightAssay | RDTL ChandigarhState lab | Feb 2022 |
| Rabeprazole Injection IP 20 mg | PE3AA11Mfg 2019-10 · Exp 2021-09 | Clarity of Solution & Particulate MatterParticulate matter | CDL KolkataCDSCO lab | Oct 2021 |
| Rabeprazole Injection IP, 20 mg WFI | PE3AA14Mfg 2020-06 · Exp 2022-05 | Description, Clarity of Solution, Particulate Matter, pH, Related Substances & AssayAssay | CDL KolkataCDSCO lab | Sep 2021 |
| Doxylamine Succinate & Pyridoxine Hydrochloride Tablets | PF8BI02Mfg 2020-03 · Exp 2022-02 | Disintegration & Assay of Doxylamine SuccinateAssay | CDL KolkataCDSCO lab | Sep 2021 |
| Ambilon 50 (Amphotericin B Liposome Injection 50 mg) | T1113A0Mfg 2020-01 · Exp 2023-12 | AssayAssay | CDL KolkataCDSCO lab | Sep 2021 |
| Doxylamine Succinate & Pyridoxine Hydrochloride Tablets | PF8B101Mfg 2019-08 · Exp 2021-07 | Disintegration TimeDisintegration | CDTL MumbaiCDSCO lab | Feb 2021 |
| Okacet-L (Levocetirizine Tablets I.P. 5 mg) | AFB8D36Mfg 2018-09 · Exp 2020-08 | Related SubstancesRelated substances | CDL KolkataCDSCO lab | Sep 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.